Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Melinta Therapeutics
300 George Street, Suite 301
New Haven, CT 06511
Phone: 203-624-5606
http://www.melinta.com/

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development of novel antibiotics that provide new and better therapeutic solutions. Melinta is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin has been designated a Qualified Infectious Disease Product (QIDP) for both ABSSSI and community-acquired bacterial pneumonia by the U.S. Food and Drug Administration. Melinta is committed to developing, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens, that cause the majority of life-threatening hospital infections.

Key Contact
Name
Mary Szela
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
06/10/15 $67,000,000 Fourth Round Malin Corporation
undisclosed